Clinical Trials
11 results for Prostate Cancer
Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease
- Condition: Prostatic Neoplasms
- Intervention: Drug: HSV-tk +Valacyclovir in Combination with Brachytherapy
- Study ID: NCT01913106
MRI-Guided HDR Brachytherapy for Prostate Cancer
- Condition: Patients With Prostate Cancer
- Intervention: Procedure: MRI Guided Needles to deliver HDR Brachytherapy, Procedure: MRI Guided Needles to deliver HDR Brachytherapy
- Study ID: NCT00913939
Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
- Condition: Prostate
- Intervention: Drug: Olaparib
- Study ID: NCT03047135
Fluorine-18 - 2-(3-(1-carboxy-5-[(6-[18F]Fluoro-pyridine-3-carbonyl)-Amino]-Pentyl)-Ureido)-Pentanedioic Acid (18F-DCFPyL) Positron Emission Tomography / Computed Tomography (PET/CT) for Assessment of Recurrent Prostate Cancer
- Condition: Prostatic Neoplasms, Prostate Cancer
- Intervention: Drug: PSMA PET/CT scan
- Study ID: NCT02899312
Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate
- Condition: Locally Recurrent Prostate Cancer
- Intervention: Radiation: Stereotactic Body Radiotherapy
- Study ID: NCT03073278
The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)
- Condition: Prostate Cancer, Cardiovascular Disease
- Study ID: NCT03127631
Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer
- Condition: Recurrent Prostate Cancer
- Study ID: NCT03067051
PSMA-PET Registry for Recurrent Prostate Cancer Following Radical Prostatectomy
- Condition: Recurrent Prostate Cancer
- Intervention: Diagnostic Test: [18F]-DCFPyL PET/ CT scan (PSMA PET)
- Study ID: NCT03718260
68Ga-PSMA-11 PET in Patients With Prostate Cancer
- Condition: Biochemically Recurrent Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Study ID: NCT04777071
A Phase 2 Study of Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: Nivolumab
- Study ID: NCT03637543
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer
- Condition: Biochemically Recurrent Prostate Cancer
- Study ID: NCT05794906